Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Deoxycholic Acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel silylation technology for UDCA purification offers high selectivity and reduced solvent consumption for pharmaceutical intermediate manufacturing supply chains.
Patent CN102718829B reveals high-yield TUDCA synthesis avoiding ion-exchange columns ensuring cost reduction and supply reliability for global pharmaceutical intermediates
Patent CN106046095B reveals mild Obeticholic acid synthesis. Eliminates LDA cryogenic steps. Enables cost reduction in pharmaceutical intermediates manufacturing.
Patent CN113480589B details a novel DMAP salt method for UDCA purification ensuring high yield and purity for reliable pharmaceutical intermediate supply chains.
Patent CN114592027A reveals a novel two-step method for Tauroursodeoxycholic Acid production, offering significant cost reduction in API manufacturing and high-purity outcomes.
Patent CN114958699A reveals a novel dual-enzyme co-expression strategy for ursodeoxycholic acid, offering superior purity and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN106831923B reveals a novel CDCA synthesis route. Discover high-purity manufacturing, supply chain reliability, and significant cost reduction strategies.
Patent CN118388570A reveals a novel enzymatic-chemical hybrid route for UDCA intermediates. Achieve superior selectivity and safety for pharmaceutical manufacturing.
Patent CN116103254B reveals stable enzyme mutants for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel synthesis of 3 beta-ursodesoxycholic acid via selective esterification and stereoselective reduction. High yield, mild conditions, cost-effective manufacturing solution.
Patent CN102660755B reveals electroreduction method for UDCA. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Novel patent CN112724189B details waste-to-value synthesis enhancing supply chain reliability and cost efficiency for global pharmaceutical intermediate procurement strategies.
Patent CN113736842B reveals high-purity TUDCA production via multi-cell catalysis. Offers cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Patent CN106701882A details a novel chemo-enzymatic route for UDCA production offering high purity and scalable manufacturing capabilities for global pharmaceutical supply chains.
Patent CN109134577B reveals a novel 4-step synthesis for lithocholic acid isomers, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN107200763B reveals a novel two-step synthesis for lithocholic acid. This method offers high purity and scalable production for pharmaceutical supply chains.
Patent CN103319560A details a high-yield UDCA synthesis from CDCA using NBS oxidation and Luche reduction, offering cost reduction in API manufacturing and reliable pharmaceutical intermediates supply.
Novel borate catalysis method for TUDCA synthesis ensures high purity and reduced cost. Scalable process for pharmaceutical intermediates supply chain optimization and reliability.
Patent CN112724189A details a novel semi-synthetic route for Chenodeoxycholic Acid from waste bile acids, offering significant cost reduction and supply chain stability for API manufacturers.
Patent CN114940964B reveals efficient UDCA production. Reduced costs and high purity for pharmaceutical supply chains.